TNF-α and the IFN-γ-inducible protein 10 (IP-10 CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma
Interferon-γ-inducible protein 10 is a potent chemoattractant for natural killer cells and activated T lymphocytes. It also displays angiostatic properties and some antitumor activity. Tumor necrosis factor-α (TNF-α) is a powerful immunomodulating cytokine with demonstrated tumoricidal activity in v...
Gespeichert in:
Veröffentlicht in: | Cancer gene therapy 2009-02, Vol.16 (2), p.149-160 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Interferon-γ-inducible protein 10 is a potent chemoattractant for natural killer cells and activated T lymphocytes. It also displays angiostatic properties and some antitumor activity. Tumor necrosis factor-α (TNF-α) is a powerful immunomodulating cytokine with demonstrated tumoricidal activity in various tumor models and the ability to induce strong immune responses. This prompted us to evaluate the antitumor effects of recombinant parvoviruses designed to deliver IP-10 or TNF-α into a glioblastoma. When Gl261 murine glioma cells were infected
in vitro
with an IP-10- or TNF-α-transducing parvoviral vector and were subcutaneously implanted in mice, tumor growth was significantly delayed. Complete tumor regression was observed when the glioma cells were coinfected with both the vectors, demonstrating synergistic antitumor activity. In an established
in vivo
glioma model, however, repeated simultaneous peritumoral injection of the IP-10- and TNF-α-delivering parvoviruses failed to improve the therapeutic effect as compared with the use of a single cytokine-delivering vector. In this tumor model, cytokine-mediated immunostimulation, rather than inhibition of vascularization, is likely responsible for the therapeutic efficacy. |
---|---|
ISSN: | 0929-1903 1476-5500 |
DOI: | 10.1038/cgt.2008.62 |